Brady Kevin M.

CFO Brady Kevin M. sold 3,000 shares of MEDP at $590.35 for $1,771,050; holds 5,830 shares post-sale (-34.0%).

Brady Kevin M. (CFO & Treasurer) executed a substantial open-market sale of 3,000 shares at $590.35 on 2025-11-21, reducing his holdings by 34.0% from 8,830 to 5,830 shares. The sale occurred near the 52-week high of $618.49 (-1.1% from peak), and MEDP stock has since appreciated 1.1% in the 30-day window post-transaction. His cross-ticker track record shows 2 prior open-market sales with a 90-day well-timed rate of 50.00%, while his MEDP-specific history (2 prior trades) included one well-timed 90-day outcome. The company's fundamentals remain solid with annual revenue growth of +11.8%, net income of $111,135,000, and a P/E of 39.81. The sale's proximity to a 52-week high and the substantial reduction in insider ownership stake warrant scrutiny of motivations and any near-term forward guidance shifts.

CFO Brady Kevin M. sells 12,000 MEDP shares for $5.5M, reducing holdings by 66.7% to 6,000 shares

Brady Kevin M., CFO & Treasurer of Medpace Holdings, sold 12,000 shares (66.7% of pre-transaction holdings) at $454.23 on 2025-07-24, totaling $5,450,760.00. The sale occurs when MEDP is at $453.05, down 5.2% from its 52-week high of $477.73, but up 45.8% over the preceding 30 days and 47.9% over 90 days. His prior sale at MEDP on 2023-07-31 was followed by a 90-day decline (well-timed at the -1.8% mark), and his cross-ticker track record shows 1 prior sell with a 100.00% well-timed rate at 90-day measurement. The company's fundamentals remain solid with annual revenue growth of +11.8%, net income of $90.3M on $603.3M quarterly revenue, and a market cap of $12.7B, though the P/E of 30.43 sits above historical norms for the sector. The magnitude of this reduction—divesting two-thirds of his holdings in a single transaction—contrasts with the company's operational strength and recent stock momentum.